This is the authors' abstract. We don't add key points for this paper.
Aflibercept in combination with FOLFIRI conferred a statistically significant survival benefit over FOLFIRI combined with placebo in patients with mCRC previously treated with oxaliplatin.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Cutsem et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: